Stocks · Healthcare · Medical - Pharmaceuticals
Royalty Pharma plc RPRX
$57.16 -0.82% Close, Oct 2, 2026 · NASDAQ · Market cap $25.34B
High qualityLow risk
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to 62.3% from 79.8% a year earlier.
- Earnings beat analyst estimates in each of the last 8 quarters (average surprise over the last four: +10.6%).
- Net debt is 4.7× EBITDA, a high level of leverage.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 48%
- EPS growth (TTM, YoY)Bottom 36%
- FCF growth (TTM, YoY)Top 43%
- Revenue growth, 3-year CAGRBottom 29%
- Revenue growth accelerationTop 26%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 16%
- Gross marginTop 20%
- Operating marginTop 1%
- Cash conversion (OCF / net income)Top 10%
- Accruals (lower is better)Top 32%
- Net debt / EBITDA (lower is better)Bottom 15%
- Interest coverTop 28%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 18%
- Free-cash-flow yieldTop 6%
- EBITDA / enterprise valueTop 22%
- Sales / enterprise valueBottom 26%
- P/E vs own 5-year history (lower is better)Bottom 30%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 25%
- 6-month returnTop 40%
- 1-year return vs S&P 500Top 25%
- Distance from 52-week highTop 18%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 37%
- Consecutive EPS beatsTop 8%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetBottom 17%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 4%
- Maximum drawdown, 3 yearsTop 1%
- Beta vs S&P 500 (lower is better)Top 5%
- Net debt / EBITDA (lower is better)Bottom 15%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 7.8% | 10.0% | ↑ |
| EPS growth (YoY) | -23.7% | -19.4% | ↑ |
| Gross margin | 100.0% | 89.4% | ↓ |
| Operating margin | 79.8% | 62.3% | ↓ |
| FCF margin | 104.4% | 117.4% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 10.0% | 7.8% | ↑ | Top 48% |
| EPS growth (TTM, YoY) | -19.4% | -23.7% | ↑ | Bottom 36% |
| Gross margin | 89.4% | 100.0% | ↓ | Top 20% |
| Operating margin | 62.3% | 79.8% | ↓ | Top 1% |
| Net margin | 32.1% | 44.3% | ↓ | — |
| Free-cash-flow margin | 117.4% | 104.4% | ↑ | — |
| Return on invested capital | 9.0% | — | Top 16% | |
| Revenue growth, 3-year CAGR | 2.1% | — | Bottom 29% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 3.00×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -10.9%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 7.8%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +3096.0 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 4.75×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 4.4×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 1.57%
- Net buyback yield (TTM)
- 1.27%
- Shareholder yield
- 2.84%
- Share count change, 1 year
- -1.0%
- Share count change, 3-year CAGR
- -2.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 8
- Beats in the last 8 reports
- 8 of 8
- Average EPS surprise, last 4
- +10.6%
- Average 2-day reaction, last 8
- +0.7%
- Positive 20 days after report
- 6 of 8
Analysts
- Consensus price target
- $62.67
- Target vs current price
- +9.6%
- Analysts with a rating
- 11
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | +3.9% | +0.5% | +0.5% | +8.4% | — |
| May 6, 2026 | +7.4% | +0.6% | +2.5% | +9.0% | +15.8% |
| Feb 11, 2026 | +13.2% | +0.1% | +2.6% | +5.6% | +13.5% |
| Nov 5, 2025 | +17.7% | +6.8% | +3.0% | +4.7% | +11.9% |
| Aug 6, 2025 | +10.7% | -2.1% | -5.4% | -3.3% | -3.3% |
| May 8, 2025 | +11.2% | +1.1% | -1.4% | +3.1% | +15.7% |
| Feb 11, 2025 | +16.2% | +1.7% | +3.6% | +2.3% | +3.2% |
| Nov 6, 2024 | +12.1% | -3.3% | -5.6% | -5.2% | +13.5% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | $1.32 | $1.27 | +3.9% | $773.0M |
| May 6, 2026 | $1.30 | $1.21 | +7.4% | $925.0M |
| Feb 11, 2026 | $1.46 | $1.29 | +13.2% | $874.0M |
| Nov 5, 2025 | $1.17 | $0.99 | +17.7% | $609.3M |
| Aug 6, 2025 | $1.14 | $1.03 | +10.7% | $578.7M |
| May 8, 2025 | $1.06 | $0.95 | +11.2% | $568.2M |
| Feb 11, 2025 | $1.15 | $0.99 | +16.2% | $594.0M |
| Nov 6, 2024 | $1.04 | $0.93 | +12.1% | $564.7M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 32.9× | 27.4× | 65th | Top 18% |
| P/E (forward) | 10.7× | — | — | — |
| EV / EBITDA | 19.5× | — | — | Top 22% |
| EV / Sales | 13.20× | — | — | Bottom 26% |
| Free-cash-flow yield | 11.75% | — | — | Top 6% |
| Earnings yield | 3.04% | — | — | Top 18% |
P/E over the past five years
Range 10.4× – 153.4× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +57.4%
- Earnings per share growth (TTM)
- -19.4%
- Change in P/E multiple
- +93.1%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 434
- 50-day average slope (20 days)
- +1.1%
- 200-day average slope (20 days)
- +4.0%
- Distance from 50-day average
- -3.8%
- Distance from 200-day average
- +11.9%
- RSI (14)
- 36.9
- Relative volume
- 0.67×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 24.0%
- Volatility vs own 5-year history
- 59th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.18
- Correlation with S&P 500
- 0.13
- Current drawdown from 1-year high
- -10.6%
- Maximum drawdown, 3 years
- -22.5%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jan 26, 2021 | Dec 19, 2024 | -54.0% | 982 days | 348 days (May 13, 2026) |
| Oct 13, 2020 | Oct 28, 2020 | -19.4% | 11 days | 30 days (Dec 10, 2020) |
| Sep 4, 2026 | Oct 2, 2026 | -10.6% | 19 days | Not yet recovered |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $25.34B
- P/E (TTM)
- 32.9
- EPS, diluted (TTM)
- $1.74
- Revenue (TTM)
- $2.54B
- Dividend yield
- 1.62%
- 52-week range
- $35.23 – $64.38
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $2.29B | $2.24B | $2.35B | $2.26B | $2.38B |
| Gross profit | $2.29B | $2.24B | $2.35B | $2.26B | $2.38B |
| Operating income | $1.43B | $307.1M | $1.49B | $1.29B | $1.56B |
| Net income | $619.7M | $42.8M | $1.13B | $859.0M | $770.9M |
| EPS (diluted) | $1.49 | $0.10 | $2.53 | $1.91 | $1.80 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $564.7M | $593.6M | $568.2M | $578.7M | $609.3M | $622.0M | $630.6M | $674.1M |
| Net income | $544.0M | $208.2M | $238.3M | $30.2M | $288.2M | $214.2M | $295.0M | $17.9M |
| EPS (diluted) | $1.21 | $0.47 | $0.41 | $0.07 | $0.67 | $0.50 | $0.53 | $0.04 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $2.02B | $2.14B | $2.99B | $2.77B | $2.49B |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | $2.02B | $2.14B | $2.99B | $2.77B | $2.49B |
| Dividends paid | -$285.2M | -$333.3M | -$358.3M | -$376.5M | -$378.3M |
| Net share buybacks | $0 | $0 | -$304.8M | -$229.7M | -$1.23B |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $837.0M
- Total assets
- $19.82B
- Total liabilities
- $10.03B
- Total debt
- $8.96B
- Net debt
- $8.15B
- Shareholders’ equity
- $6.83B
As of Jun 30, 2026 (filed Aug 5, 2026).
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| Aug 14, 2026 | $0.24 | Sep 10, 2026 |
| May 15, 2026 | $0.24 | Jun 10, 2026 |
| Feb 20, 2026 | $0.24 | Mar 10, 2026 |
| Nov 14, 2025 | $0.22 | Dec 10, 2025 |
| Aug 15, 2025 | $0.22 | Sep 10, 2025 |
| May 16, 2025 | $0.22 | Jun 10, 2025 |
| Feb 21, 2025 | $0.22 | Mar 10, 2025 |
| Nov 15, 2024 | $0.21 | Dec 10, 2024 |
Short interest
- Shares sold short
- 11,647,565
- Days to cover
- 3.25
- Change vs previous report
- -2.1%
FINRA short interest, settlement date Sep 15, 2026.